The Precision Peptide Genetic Test removes guesswork from medication selection, potentially reducing time to effective dosing and improving long-term weight loss outcomes
Ipamorelin and tesamorelin are both growth hormone-releasing peptides, but they work through distinct biological pathways and have different clinical applications
This point is effectively made in a recently conducted large trial, which states that, our understanding of the mechanisms of cardiovascular protection with [the GLP-1 agonist] semaglutide remains speculativeclinical benefit is [thought to be] achieved through multiple interrelated pathways. Acknowledgement of this evidence gap prompted our lab, through use of a large animal model of CAD that replicates the features of disease as it occurs in humans, to investigate the cardiac consequences of semaglutide administration
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canadas health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system
This can lead to better blood sugar levels and even weight loss for some patients
Figure 4 shows the cumulative incidence curves for major adverse cardiovascular events, with a lower cumulative incidence for the GLP-1 receptor agonist-SGLT-2 inhibitor combination and the curves diverging after three months of use
